ZYME - Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums Thanks To An ADC Tailwind
2024-01-31 13:04:00 ET
Summary
- ZYME's partners, JAZZ and BGNE, are potentially within a year of approval and launch of zanidatamab, a bispecific anti-HER2 antibody.
- The approval and launch of zanidatamab in multiple markets could generate significant milestones and royalty streams for ZYME.
- ZYME projects that it has sufficient cash to last into H2 2027.
If you look at the chart of Zymeworks (ZYME) you can see that shareholders have had to wait fairly patiently for a couple years for a sustained turnaround. Now the company's US partner Jazz Pharmaceuticals ( JAZZ ) and Asia-Pacific partner, BeiGene ( BGNE ), are potentially within a year of approval and launch of zanidatamab, a bispecific anti-HER2 antibody originally developed by ZYME, with potential in several cancer types. On top of the potential approval and launch of zanidatamab in multiple markets, the company continues to work on its own pipeline members, several of which are antibody-drug conjugates (ADCs) which are a hot commodity right now. This article takes a look at the road ahead for ZYME....
Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind